I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Preliminary Cost-Effectiveness and Cost-Utility Analysis of..:
Ghetti G
;
D'Avella MC
;
Pradelli L
https://www.dovepress.com/preliminary-cost-effectiveness-and-cost-utility-analysis-of-cemiplimab-peer-reviewed-article-CEOR. , 2021
Link:
https://doaj.org/article/35d9027db1f04c73aea94fc7e7972..
RT Journal T1 <Title>Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy</Title> UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:35d9027db1f04c73aea94fc7e7972e05&Exemplar=1&LAN=DE A1 Ghetti G A1 D'Avella MC A1 Pradelli L PB Dove Medical Press YR 2021 K1 italian national health service K1 icer K1 partitioned survival model K1 non-melanoma skin cancers K1 Medicine (General) K1 R5-920 K1 Therapeutics. Pharmacology K1 RM1-950 JF https://www.dovepress.com/preliminary-cost-effectiveness-and-cost-utility-analysis-of-cemiplimab-peer-reviewed-article-CEOR LK http://dx.doi.org/https://doaj.org/article/35d9027db1f04c73aea94fc7e7972e05 DO https://doaj.org/article/35d9027db1f04c73aea94fc7e7972e05 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)
